Prolonged response to early docetaxel in a patient with biochemical relapse after primary therapy for prostate cancer and incomplete response to androgen suppression therapy

Christine M. Barnett, Jason F. Flamiatos, Tomasz M. Beer

Research output: Contribution to journalArticlepeer-review

Abstract

Sensitivity to androgen suppression therapy (AST) is a key determinant of survival in patients with nonlocalized prostate cancer. While an incomplete response to AST is associated with poor survival, additional therapy is typically withheld until obvious cancer progression. It is not known if the application of additional therapy earlier can have a favorable impact on long-term outcomes. We present the case of a patient with biochemically relapsed prostate cancer treated with early docetaxel after initial incomplete response to AST who now has a prolonged response to therapy.

Original languageEnglish (US)
Pages (from-to)973-974
Number of pages2
JournalAnticancer research
Volume31
Issue number3
StatePublished - Mar 1 2011

Keywords

  • Biochemical relapse
  • Chemotherapy
  • Docetaxel
  • Prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Prolonged response to early docetaxel in a patient with biochemical relapse after primary therapy for prostate cancer and incomplete response to androgen suppression therapy'. Together they form a unique fingerprint.

Cite this